Rice Hall James & Associates LLC Reduces Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Rice Hall James & Associates LLC lessened its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 2.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 264,031 shares of the company’s stock after selling 7,866 shares during the quarter. Rice Hall James & Associates LLC’s holdings in UroGen Pharma were worth $2,812,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in URGN. SG Americas Securities LLC purchased a new stake in shares of UroGen Pharma during the 3rd quarter valued at about $179,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of UroGen Pharma in the third quarter worth approximately $249,000. Intech Investment Management LLC purchased a new position in shares of UroGen Pharma in the third quarter worth approximately $155,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of UroGen Pharma by 9.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 90,493 shares of the company’s stock worth $1,149,000 after buying an additional 7,576 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Insider Activity

In other news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Analysts Set New Price Targets

Separately, D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Tuesday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, UroGen Pharma presently has an average rating of “Buy” and an average price target of $43.70.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $10.56 on Wednesday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 1-year low of $9.78 and a 1-year high of $20.70. The firm’s 50 day simple moving average is $10.79 and its two-hundred day simple moving average is $12.26.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.